GHK-Cu

What it is

GHK-Cu is a short chain of three amino acids, glycine, histidine, and lysine, with a single copper ion attached. It occurs naturally in the human body and can be measured in blood plasma, saliva, and urine. Researchers have measured plasma levels around 200 nanograms per milliliter in a twenty-year-old, falling to roughly 80 nanograms per milliliter by age sixty, a decline that helped draw research interest toward skin and tissue aging.

Scientists classify GHK-Cu as a copper-binding tripeptide. Laboratory work has focused on its effect on fibroblasts, the skin cells that manufacture collagen, and on how broadly it changes gene activity when applied to cells. Review papers describe copper-peptide research touching a very large share of genes studied, some turned up and some turned down, and that spread is why the compound gets described as having broad rather than narrow reach.

How it is studied

The GHK-Cu literature is built mostly from laboratory work: cells grown in a dish, review papers summarizing gene-activity data, and topical, skin-applied studies rather than injectable human trials. Injectable use in people has not been approved by any medicines regulator, and independent clinical trial data on that route is limited. Most of what is published instead comes from cell-culture experiments and topical formulation studies looking at skin and wound-related outcomes.

What studies report

• A review of the gene-expression literature reported that GHK affects roughly three in ten of the genes examined, with somewhat more turned on than turned off, a pattern the authors described as broadly regenerative across several tissue types [1]. [1]
• A cell-culture study found that adding GHK-Cu to human skin fibroblasts increased the cells' production of collagen and elastin, the two structural proteins that give skin its firmness [2]. [2]
• A separate review reported that GHK could reset the gene activity of unhealthy cells toward a healthier pattern, including increasing genes involved in DNA repair and reversing a gene-activity signature associated with chronic lung disease [3]. [3]

What is not known

Most of the cited evidence for GHK-Cu comes from cells grown in a dish or from review articles summarizing gene-activity data, not from large controlled trials in whole people. How well laboratory findings on collagen production or gene activity translate into a measurable change in skin appearance over time in a general population is not settled by these papers alone. Injectable use of GHK-Cu in people carries far less published data than topical use, and safety information for that route is correspondingly thin.

Regulatory status

No form of GHK-Cu, injectable or topical, is approved by the United States Food and Drug Administration as a drug. Topical copper-peptide products are available in some markets as cosmetic ingredients, which follow a lighter regulatory path than medicines and do not require the same proof of effect. The World Anti-Doping Agency has not placed GHK-Cu on its roster of banned substances.